Solventum Acquires Acera Surgical

Seneca Partners Invests £1.2m in SolasCure

August 18, 2021

Biotechnology

Seneca Partners has invested £1.2 million into Cambridge-based biotech start-up SolasCure to support development of its wound‑care product Aurase. The funding (via Seneca EIS Portfolio Service and Seneca Growth Capital VCT) will help SolasCure progress Aurase into clinical trial stages.

BioStem Technologies Acquires BioTissue's Surgical and Wound Care Business

January 22, 2026

Medical Devices

BioStem Technologies (OTC: BSEM) has acquired the surgical and wound care business of BioTissue Holdings, Inc. for approximately $15 million upfront, with up to $25 million of contingent milestone and royalty payments. The deal includes the Neox and Clarix product lines, a nationwide commercial sales organization and assigned GPO contracts, expanding BioStem's access into hospital inpatient and outpatient wound-care markets and adding assets that generated roughly $29 million in 2025.

Essity Acquires Hydrofera to Expand Advanced Wound Care Portfolio

December 29, 2021

Medical Devices

Essity has acquired US-based advanced wound care company Hydrofera for USD 116 million, with a potential additional earnout of up to USD 15 million. Hydrofera, headquartered in Manchester, Connecticut with about 90 employees, brings Hydrofera Blue antibacterial wound dressings and distribution relationships across hospitals, clinics and long-term care—supporting Essity's Medical Solutions capability expansion.

Convatec Group Acquires Triad Life Sciences

January 28, 2022

Medical Devices

Convatec Group Plc has signed a definitive agreement to acquire Triad Life Sciences Inc, a Memphis-based developer and manufacturer of porcine placenta‑derived extracellular matrix products for advanced wound care. The deal, expected to close in Q1 2022 subject to regulatory approvals, values Triad at an initial $125 million with up to $275 million additional contingent/earnout payments tied to milestones and performance.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

Biosynth Acquires celares to Expand Bioconjugation and Polymer Drug Delivery Capabilities

July 11, 2023

Biotechnology

Biosynth, a Switzerland-based supplier of critical raw materials and manufacturing services, acquired Berlin-based celares, a developer and manufacturer of bioconjugates, activated PEGs and polymer-based drug delivery excipients. The acquisition strengthens Biosynth's capabilities in conjugate vaccines and bioconjugate drugs and adds GMP bioconjugation and PEGylation manufacturing in Berlin to its service offering.